Amolyt is developing therapeutic peptides for rare endocrine and related diseases, including AZP-3601 (eneboparatide) for hypoparathyroidism Proceeds will fund the Phase 3 programme for hypoparathyroidism, as well as its growing endocrine pipeline Copenhagen, Denmark – Novo Holdings A/S, a leading international life sciences investor, has announced it has invested in a €130 million (approx. $138 million) […]
COPENHAGEN, DENMARK — Novo Holdings, a leading international life science investor, today announced a $40m investment in Evosep, the bioscience company leading the standardisation of proteomics for clinical use. The proceeds from the investment by Novo Holdings will be used to advance clinical applications of proteomics enabled by Evosep’s standardised liquid chromatography platform. The new […]
Early data read out indicates a successful LPS human challenge trial Key Highlights · POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo · A clear dose-response relationship was demonstrated · Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported · Full […]
AMSTERDAM, THE NETHERLANDS, 5 January 2023 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), today announced the signing of a licensing agreement with Amgen to develop next generation ADCs. Amgen will gain access to Synaffix’s antibody conjugation technology platforms comprising GlycoConnect™, HydraSpace™ and select […]
Updated clinical data demonstrates a prolonged and sustained favorable safety profile for roginolisib (IOA-244) Clinical data shows a comparable safety profile in both solid and hematologic malignancies Clinical responses seen in both solid and hematologic malignancies US FDA grants Orphan Drug Designation for IOA-244 in uveal melanoma Geneva, Switzerland and Amsterdam, The Netherlands, 5 January – iOnctura, a […]
